Sökning: onr:"swepub:oai:prod.swepub.kib.ki.se:128612187" >
A gene expression s...
A gene expression signature to predicit overall, prostate cancer, and non-prostate cancer survival
-
Li, CD (författare)
-
Peng, ZC (författare)
-
Skoog, L (författare)
-
visa fler...
-
Hellborg, H (författare)
-
Wingmo, II (författare)
-
Hjelm-Eriksson, M (författare)
-
Harmenberg, U (författare)
-
Cohn-Cedermark, G (författare)
-
Ahrlund-Richter, L (författare)
-
Pramana, S (författare)
-
Pawitan, Y (författare)
-
- Nister, M (författare)
- Karolinska Institutet
-
Nilsson, S (författare)
-
visa färre...
-
(creator_code:org_t)
- American Society of Clinical Oncology (ASCO), 2013
- 2013
- Engelska.
-
Ingår i: JOURNAL OF CLINICAL ONCOLOGY. - : American Society of Clinical Oncology (ASCO). - 0732-183X .- 1527-7755. ; 31:6
- Relaterad länk:
-
http://kipublication...
-
visa fler...
-
https://doi.org/10.1...
-
visa färre...
Abstract
Ämnesord
Stäng
- 51 Background: For prostate cancer patients, prostate cancer specific and non-prostate cancer specific survival have the same importance. This study aimed at identifying expression biomarkers that can predict prostate cancer specific, non-prostate cancer specific and overall survival at diagnosis. Methods: Selected ESCGPs (embryonic stem cell gene predictors) and control genes were analyzed by multiplex quantitative PCR using prostate fine-needle aspiration samples taken at diagnosis from a Swedish cohort of 189 prostate cancer patients diagnosed between 1986 and 2000. Of all patients, 97.9% had overall and cancer-specific survival data and 77.9% were primarily treated only by hormone therapy. The cohort was divided into one discovery and two validation subsets. Univariate and multivariate Cox proportional hazard ratios and Kaplan-Meier plots were used for the survival analysis. A published dataset was used for external validation. Results: An expression signature of F3, VGLL3 and IGFBP3, was sufficient to categorize the patients into high-risk, intermediate-risk and low-risk subtypes. The median overall survival of the subtypes was 3.23, 4.00 and 9.85 years respectively. The difference corresponded to HRs of 5.86 (95% CI 2.91-11.78, P<0.001) for the high-risk and 3.45 (95% CI 1.79-6.66, P<0.001) for the intermediate-risk compared to the low-risk subtype. This signature is significant in correlation to overall, cancer-specific and non-cancer specific survival in both univariate and multivariate analyses including common clinical parameters. Conclusions: These results suggest that these novel expression biomarkers and the expression signature could be used to improve the accuracy of the currently available clinical tools for predicting overall, cancer-specific and non-cancer specific survival and selecting patients with potential survival benefit from hormone treatment.
Publikations- och innehållstyp
- vet (ämneskategori)
- kon (ämneskategori)
Hitta via bibliotek
Till lärosätets databas
- Av författaren/redakt...
-
Li, CD
-
Peng, ZC
-
Skoog, L
-
Hellborg, H
-
Wingmo, II
-
Hjelm-Eriksson, ...
-
visa fler...
-
Harmenberg, U
-
Cohn-Cedermark, ...
-
Ahrlund-Richter, ...
-
Pramana, S
-
Pawitan, Y
-
Nister, M
-
Nilsson, S
-
visa färre...
- Artiklar i publikationen
-
JOURNAL OF CLINI ...
- Av lärosätet
-
Karolinska Institutet